▁British 10.375
▁Bi 10.8359375
ote 5.5859375
ch 4.51171875
’ 21.484375
s 7.01171875
▁Mar 10.25
im 8.46875
ast 11.3203125
at 2.814453125
▁anti 8.8125
- 0.70556640625
can 3.623046875
cer 0.2366943359375
▁treatment 5.37890625
▁will 6.65234375
▁be 1.0869140625
▁review 6.2578125
ed 0.054168701171875
▁at 2.443359375
▁the 0.9345703125
▁up 2.58203125
coming 0.10321044921875
▁European 3.255859375
▁Society 1.7265625
▁for 0.61572265625
▁Medical 0.440185546875
▁On 0.5625
col 0.0012426376342773438
ogy 0.0007600784301757812
▁( 1.263671875
ES 0.264892578125
MO 0.5087890625
) 0.106689453125
▁conference 4.3046875
▁in 0.74462890625
▁Vienna 2.84765625
. 1.49609375
▁The 1.9853515625
▁top 7.06640625
ical 0.94189453125
▁gel 3.482421875
- 5.62890625
based 0.82177734375
▁treatment 1.2666015625
, 1.6748046875
▁originally 5.6953125
▁developed 0.3876953125
▁to 1.8095703125
▁treat 0.99072265625
▁breast 4.203125
▁cancer 0.9287109375
, 0.398681640625
▁has 1.5732421875
▁shown 2.130859375
▁prom 2.388671875
ising 0.0006580352783203125
▁results 0.6708984375
▁in 0.294189453125
▁clin 3.62890625
ical 0.01541900634765625
▁tri 0.1705322265625
als 0.0002460479736328125
. 1.935546875
<0x0A> 0.763671875
Mar 5.9609375
im 0.1553955078125
ast 0.00861358642578125
at 0.0018396377563476562
▁is 1.1181640625
▁a 0.84423828125
▁matrix 8.0546875
▁metal 0.88232421875
lo 0.004123687744140625
prote 0.0263519287109375
in 0.08221435546875
ase 0.00738525390625
▁in 0.79248046875
hib 0.00013875961303710938
itor 0.0020656585693359375
, 1.8486328125
▁which 0.75048828125
▁means 3.197265625
▁it 0.48974609375
▁targets 3.841796875
▁en 2.537109375
zym 0.00024044513702392578
es 0.005397796630859375
▁that 0.56640625
▁play 3.265625
▁a 0.281494140625
▁role 0.53466796875
▁in 0.00913238525390625
▁the 1.0693359375
▁growth 2.27734375
▁and 0.767578125
▁spread 0.467041015625
▁of 0.0882568359375
▁cancer 0.422607421875
▁cells 0.537109375
. 0.12030029296875
▁In 2.91796875
▁pre 3.015625
cl 0.306640625
in 7.855892181396484e-05
ical 0.0013761520385742188
▁studies 0.56201171875
, 0.1834716796875
▁it 1.740234375
▁was 1.2109375
▁shown 0.7890625
▁to 0.09136962890625
▁in 1.5390625
hib 0.0017528533935546875
it 0.000797271728515625
▁the 0.69580078125
▁growth 0.7470703125
▁of 0.2071533203125
▁tum 2.978515625
ors 1.3203125
▁and 2.189453125
▁reduce 2.6484375
▁the 0.79345703125
▁ch 7.1796875
ances 0.0032672882080078125
▁of 0.101318359375
▁met 2.25390625
ast 0.00040984153747558594
asis 0.30810546875
. 0.95263671875
<0x0A> 0.64794921875
The 1.6171875
▁gel 2.5546875
- 1.4150390625
based 0.051513671875
▁form 1.5927734375
ulation 0.17919921875
▁allows 4.2890625
▁the 1.28125
▁drug 1.181640625
▁to 0.06146240234375
▁be 1.3330078125
▁applied 1.65234375
▁top 2.81640625
ically 0.0015134811401367188
▁to 1.3662109375
▁the 0.352294921875
▁breast 6.55859375
▁area 4.12890625
, 0.91162109375
▁which 2.5390625
▁could 3.916015625
▁reduce 2.65234375
▁the 0.61767578125
▁side 1.8662109375
▁effects 0.0679931640625
▁associated 1.228515625
▁with 0.0017843246459960938
▁traditional 2.990234375
▁chem 0.94775390625
other 0.0304107666015625
apy 0.1552734375
▁treat 2.078125
ments 5.924701690673828e-05
. 0.33837890625
▁The 2.17578125
▁treatment 2.6484375
▁is 1.0078125
▁applied 3.291015625
▁using 3.9453125
▁a 0.2303466796875
▁patch 4.75390625
, 1.4521484375
▁applied 5.71875
▁to 1.4140625
▁the 0.145263671875
▁breast 2.294921875
▁area 1.2666015625
▁daily 4.0
▁for 0.88134765625
▁two 2.400390625
▁weeks 0.215576171875
▁prior 5.703125
▁to 0.00836181640625
▁surg 1.8037109375
ery 0.0190582275390625
. 0.71484375
<0x0A> 0.66845703125
The 1.5185546875
▁phase 5.0078125
▁II 1.873046875
▁clin 1.6357421875
ical 0.000370025634765625
▁trial 0.1490478515625
▁conducted 4.94140625
▁on 3.18359375
▁ 0.341796875
2 1.748046875
0 1.6064453125
9 4.29296875
▁women 0.984375
▁with 0.68798828125
▁breast 1.400390625
▁cancer 0.014739990234375
▁showed 1.5205078125
▁a 2.517578125
▁significant 1.837890625
▁improvement 1.86328125
▁in 0.045440673828125
▁disease 3.529296875
- 0.25390625
free 0.05596923828125
▁surv 0.311279296875
ival 0.001598358154296875
▁and 1.564453125
▁overall 0.45263671875
▁surv 0.0165863037109375
ival 0.0010843276977539062
▁rates 2.623046875
. 1.5048828125
▁After 4.88671875
▁three 3.076171875
▁years 0.165283203125
, 0.372802734375
▁the 1.455078125
▁patients 4.1171875
▁who 1.328125
▁received 0.46337890625
▁Mar 2.19921875
im 0.000843048095703125
ast 0.0026683807373046875
at 0.0008988380432128906
▁had 0.87890625
▁a 0.303955078125
▁ 0.58642578125
3 1.634765625
5 2.296875
% 0.708984375
▁reduction 1.408203125
▁in 0.012664794921875
▁the 0.7294921875
▁risk 0.301513671875
▁of 0.0266876220703125
▁disease 2.06640625
▁rec 0.5390625
urrence 0.00479888916015625
▁compared 1.1689453125
▁to 0.251220703125
▁the 1.2265625
▁place 2.20703125
bo 0.0027408599853515625
▁group 0.1864013671875
. 0.494873046875
<0x0A> 0.736328125
The 1.365234375
▁treatment 2.94921875
▁also 2.458984375
▁showed 1.4765625
▁promise 4.17578125
▁in 0.32861328125
▁delay 5.21875
ing 0.00012099742889404297
▁the 0.52587890625
▁pro 2.78125
gression 0.005191802978515625
▁of 0.0555419921875
▁triple 6.62109375
- 0.80615234375
negative 0.004131317138671875
▁breast 0.0538330078125
▁cancer 0.08087158203125
, 0.9814453125
▁a 1.390625
▁particularly 3.0390625
▁ag 0.24951171875
gress 0.0002987384796142578
ive 6.651878356933594e-05
▁form 0.6162109375
▁of 0.0288543701171875
▁the 0.37646484375
▁disease 0.0709228515625
▁with 3.85546875
▁limited 2.501953125
▁treatment 0.2705078125
▁options 0.0103759765625
. 0.130859375
▁The 1.8642578125
▁results 2.49609375
▁of 1.2412109375
▁the 0.281982421875
▁clin 3.095703125
ical 0.0008988380432128906
▁trial 0.1112060546875
▁were 0.84423828125
▁published 0.9638671875
▁in 0.2127685546875
▁the 0.276611328125
▁Lanc 3.484375
et 0.00012826919555664062
▁On 0.340576171875
col 0.0011720657348632812
ogy 6.890296936035156e-05
▁journal 1.0966796875
▁earlier 3.58203125
▁this 0.0606689453125
▁year 0.82470703125
. 0.10662841796875
<0x0A> 0.08642578125
Pro 5.484375
f 0.1624755859375
essor 0.2666015625
▁Jud 7.04296875
ith 0.1756591796875
▁Bl 6.82421875
iss 1.62109375
▁of 3.568359375
▁the 0.64453125
▁Institute 2.80859375
▁of 0.053802490234375
▁Can 0.06622314453125
cer 4.5299530029296875e-05
▁Research 0.0458984375
, 1.2333984375
▁one 4.58203125
▁of 0.0022373199462890625
▁the 0.016510009765625
▁lead 2.455078125
▁investig 1.3740234375
ators 0.0009260177612304688
▁of 1.01953125
▁the 0.01399993896484375
▁clin 1.8720703125
ical 0.0005269050598144531
▁trial 0.09381103515625
, 0.09515380859375
▁commented 2.7421875
: 0.98828125
▁" 0.1514892578125
The 1.9912109375
▁results 1.3134765625
▁of 0.471435546875
▁this 0.7255859375
▁clin 2.041015625
ical 0.00098419189453125
▁trial 0.055755615234375
▁demonstrate 2.84375
▁the 1.2109375
▁potential 0.7568359375
▁of 0.325927734375
▁Mar 0.7265625
im 0.0006971359252929688
ast 0.0011539459228515625
at 0.00042748451232910156
▁to 0.96728515625
▁improve 1.921875
▁surv 2.365234375
ival 0.0033416748046875
▁rates 1.9970703125
▁for 0.79150390625
▁women 0.72265625
▁with 0.1842041015625
▁breast 0.470703125
▁cancer 0.0028743743896484375
. 1.072265625
▁It 2.609375
’ 27.3125
s 0.10565185546875
▁exc 4.59765625
iting 0.0009183883666992188
▁to 0.458984375
▁see 0.457763671875
▁a 2.224609375
▁novel 3.89453125
▁treatment 0.93115234375
▁like 3.431640625
▁Mar 0.70947265625
im 0.0008983612060546875
ast 0.001674652099609375
at 0.0010862350463867188
▁showing 3.896484375
▁such 0.91650390625
▁prom 2.1953125
ising 0.0002796649932861328
▁results 0.18408203125
." 2.126953125
<0x0A> 0.087646484375
The 1.732421875
▁ES 5.24609375
MO 0.0018291473388671875
▁conference 0.61962890625
, 2.408203125
▁which 0.50634765625
▁is 1.548828125
▁being 1.2158203125
▁held 0.0413818359375
▁from 2.140625
▁ 0.83447265625
2 1.1015625
5 2.484375
th 1.91015625
▁September 2.224609375
▁to 0.2666015625
▁ 0.035308837890625
2 0.96923828125
9 1.0888671875
th 0.0145111083984375
▁September 0.01885986328125
, 0.912109375
▁brings 3.318359375
▁together 0.049072265625
▁leading 2.548828125
▁on 2.9296875
colog 1.1708984375
ists 0.02301025390625
▁and 1.0458984375
▁medical 2.642578125
▁profession 1.263671875
als 0.0003032684326171875
▁to 1.5576171875
▁discuss 0.395263671875
▁the 0.5576171875
▁latest 0.21240234375
▁develop 1.7080078125
ments 6.747245788574219e-05
▁in 0.1279296875
▁cancer 0.591796875
▁treat 2.396484375
ments 0.0003464221954345703
▁and 1.826171875
▁research 0.83544921875
. 0.075927734375
<0x0A> 0.76904296875
The 2.259765625
▁review 7.953125
▁of 0.458740234375
▁Mar 0.8173828125
im 0.0016279220581054688
ast 0.0025005340576171875
at 0.003620147705078125
▁is 2.7578125
▁expected 2.388671875
▁to 0.09625244140625
▁generate 6.26953125
▁significant 2.986328125
▁interest 0.294189453125
▁among 1.994140625
▁the 2.1640625
▁health 5.3984375
care 0.1358642578125
▁community 1.0263671875
, 0.99951171875
▁with 1.73046875
▁the 1.4130859375
▁potential 1.2978515625
▁to 0.5458984375
▁open 3.73828125
▁up 0.59716796875
▁a 1.5283203125
▁new 0.1746826171875
▁a 2.134765625
venue 0.002719879150390625
▁of 0.9345703125
▁treatment 0.488037109375
▁for 0.2037353515625
▁breast 0.634765625
▁cancer 0.00867462158203125
▁patients 0.53564453125
. 0.1685791015625
<0x0A> 0.50634765625
" 3.77734375
Mar 1.5400390625
im 0.0024776458740234375
ast 0.0014495849609375
at 0.002689361572265625
▁has 2.53515625
▁the 0.8291015625
▁potential 0.0213775634765625
▁to 0.01470184326171875
▁make 3.888671875
▁a 0.138427734375
▁real 1.625
▁difference 0.1282958984375
▁to 0.60302734375
▁the 0.6552734375
▁lives 0.2293701171875
▁of 0.00457000732421875
▁millions 6.08984375
▁of 0.042572021484375
▁women 0.77685546875
▁around 2.20703125
▁the 0.00035691261291503906
▁world 0.026824951171875
▁who 1.697265625
▁are 0.53369140625
▁living 2.11328125
▁with 0.004642486572265625
▁breast 0.307861328125
▁cancer 0.0014438629150390625
," 0.53369140625
▁said 0.61279296875
▁Dr 1.71484375
. 1.3056640625
▁Tom 5.30078125
▁Brad 6.93359375
sh 2.21875
aw 0.0021209716796875
, 0.177490234375
▁CE 2.322265625
O 0.00017559528350830078
▁of 0.2369384765625
▁British 6.8984375
▁Bi 1.521484375
ote 0.0074310302734375
ch 0.049530029296875
. 0.91943359375
▁" 0.64501953125
We 0.90185546875
’ 27.40625
re 0.87744140625
▁thr 2.47265625
illed 0.00014257431030273438
▁to 0.262451171875
▁have 1.224609375
▁the 2.103515625
▁opportunity 0.34375
▁to 0.00811767578125
▁present 1.2373046875
▁our 1.908203125
▁find 2.763671875
ings 7.832050323486328e-05
▁at 0.37060546875
▁the 0.63330078125
▁ES 0.4072265625
MO 0.0013265609741210938
▁conference 0.272705078125
▁and 1.3466796875
▁look 1.4404296875
▁forward 0.0047454833984375
▁to 0.002162933349609375
▁discuss 2.052734375
ing 0.004039764404296875
▁the 0.65673828125
▁potential 1.255859375
▁of 0.52734375
▁Mar 0.485107421875
im 0.0012636184692382812
ast 0.0017518997192382812
at 0.005031585693359375
▁with 0.8583984375
▁the 1.3486328125
▁on 2.91015625
col 0.61376953125
ogy 8.487701416015625e-05
▁community 0.06781005859375
." 0.29248046875
<0x0A> 0.11572265625
Bre 4.11328125
ast 0.020050048828125
▁cancer 0.80419921875
▁is 0.6767578125
▁the 0.1878662109375
▁most 0.2467041015625
▁common 0.2401123046875
▁cancer 0.5439453125
▁in 0.6396484375
▁women 0.348876953125
▁world 0.97705078125
wide 0.00432586669921875
, 0.62255859375
▁with 0.646484375
▁approximately 2.498046875
▁ 0.1722412109375
2 1.845703125
. 0.89306640625
1 1.984375
▁million 0.05718994140625
▁new 0.418212890625
▁cases 0.062347412109375
▁diagn 1.0712890625
osed 0.001033782958984375
▁each 0.70703125
▁year 0.0002830028533935547
. 0.1591796875
▁While 3.875
▁traditional 4.80859375
▁treat 2.12890625
ments 7.474422454833984e-05
▁such 1.28125
▁as 0.005039215087890625
▁chem 0.349609375
other 0.01318359375
apy 0.0051422119140625
▁and 0.787109375
▁radiation 0.71044921875
▁ther 1.25
apy 0.01293182373046875
▁have 1.2890625
▁improved 3.2734375
▁surv 0.59423828125
ival 0.0019483566284179688
▁rates 0.049652099609375
, 0.490234375
▁they 1.271484375
▁are 1.5400390625
▁often 1.7666015625
▁associated 1.1748046875
▁with 0.00119781494140625
▁significant 1.2744140625
▁side 0.054656982421875
▁effects 0.022705078125
. 1.2431640625
<0x0A> 0.703125
The 2.60546875
▁potential 3.251953125
▁for 1.89453125
▁a 2.83984375
▁top 1.58203125
ical 0.0120697021484375
▁gel 1.09765625
- 0.2437744140625
based 0.00710296630859375
▁treatment 0.2034912109375
▁like 1.1611328125
▁Mar 0.007350921630859375
im 0.0006594657897949219
ast 0.0021038055419921875
at 0.0005598068237304688
▁to 0.82861328125
▁offer 2.056640625
▁a 0.77490234375
▁more 1.42578125
▁target 1.630859375
ed 0.00110626220703125
▁and 1.111328125
▁less 0.82470703125
▁invas 0.62060546875
ive 2.4199485778808594e-05
▁treatment 0.96142578125
▁option 1.3701171875
▁is 1.7978515625
▁a 1.9814453125
▁significant 1.6044921875
▁development 1.333984375
▁in 0.62890625
▁the 0.395263671875
▁fight 0.86767578125
▁against 0.0238189697265625
▁breast 0.178955078125
▁cancer 0.0013027191162109375
. 0.090576171875
<0x0A> 0.806640625
The 2.447265625
▁review 2.583984375
▁of 0.333251953125
▁Mar 0.174072265625
im 0.0014820098876953125
ast 0.0019502639770507812
at 0.0010700225830078125
▁at 2.345703125
▁the 0.3349609375
▁ES 0.216796875
MO 0.0018033981323242188
▁conference 0.058807373046875
▁will 1.2490234375
▁provide 2.34765625
▁an 1.650390625
▁opportunity 0.81103515625
▁for 0.2139892578125
▁health 1.560546875
care 0.048675537109375
▁profession 0.07586669921875
als 9.179115295410156e-06
▁to 0.42236328125
▁consider 5.9140625
▁the 0.315185546875
▁potential 0.2054443359375
▁benefits 2.259765625
▁of 0.3779296875
▁the 0.80615234375
▁treatment 0.268310546875
▁and 1.4150390625
▁to 1.814453125
▁discuss 0.64599609375
▁the 1.23828125
▁next 3.20703125
▁steps 0.024993896484375
▁in 0.4267578125
▁its 1.083984375
▁development 0.09625244140625
. 0.08709716796875
▁With 4.2578125
▁the 0.97998046875
▁prospect 7.18359375
▁of 0.11175537109375
▁impro 3.90625
ving 0.00023984909057617188
▁surv 0.52490234375
ival 0.0037059783935546875
▁rates 0.0211181640625
▁for 1.021484375
▁breast 0.52099609375
▁cancer 0.00141143798828125
▁patients 0.0284576416015625
, 0.1749267578125
▁the 1.30859375
▁potential 1.3564453125
▁of 1.5400390625
▁Mar 0.339111328125
im 0.0006694793701171875
ast 0.0018157958984375
at 0.0013017654418945312
▁is 1.36328125
▁a 3.2578125
▁be 8.2734375
acon 0.07061767578125
▁of 0.35107421875
▁hope 0.021514892578125
▁for 0.2080078125
▁millions 3.44140625
▁of 0.1943359375
▁women 0.388427734375
▁around 0.74853515625
▁the 0.00018799304962158203
▁world 0.0269775390625
. 0.1492919921875
